[go: up one dir, main page]

WO2005058950A3 - Methods for generating immunity to antigen - Google Patents

Methods for generating immunity to antigen Download PDF

Info

Publication number
WO2005058950A3
WO2005058950A3 PCT/US2004/041690 US2004041690W WO2005058950A3 WO 2005058950 A3 WO2005058950 A3 WO 2005058950A3 US 2004041690 W US2004041690 W US 2004041690W WO 2005058950 A3 WO2005058950 A3 WO 2005058950A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
fusion protein
immune response
methods
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/041690
Other languages
French (fr)
Other versions
WO2005058950A2 (en
Inventor
Albert Deisseroth
Yucheng Tang
Wei-Wei Zhang
Xiang-Ming Fang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sidney Kimmel Cancer Center
Original Assignee
Sidney Kimmel Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidney Kimmel Cancer Center filed Critical Sidney Kimmel Cancer Center
Priority to EP04813939A priority Critical patent/EP1720905A2/en
Priority to JP2006544078A priority patent/JP2008504219A/en
Priority to CA002548347A priority patent/CA2548347A1/en
Publication of WO2005058950A2 publication Critical patent/WO2005058950A2/en
Publication of WO2005058950A3 publication Critical patent/WO2005058950A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.
PCT/US2004/041690 2003-12-11 2004-12-10 Methods for generating immunity to antigen Ceased WO2005058950A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04813939A EP1720905A2 (en) 2003-12-11 2004-12-10 Methods for generating immunity to antigen
JP2006544078A JP2008504219A (en) 2003-12-11 2004-12-10 Methods for raising immunity against an antigen
CA002548347A CA2548347A1 (en) 2003-12-11 2004-12-10 Methods for generating immunity to antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59201603P 2003-12-11 2003-12-11
US60/592,016 2004-07-29

Publications (2)

Publication Number Publication Date
WO2005058950A2 WO2005058950A2 (en) 2005-06-30
WO2005058950A3 true WO2005058950A3 (en) 2006-03-02

Family

ID=34700248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041690 Ceased WO2005058950A2 (en) 2003-12-11 2004-12-10 Methods for generating immunity to antigen

Country Status (3)

Country Link
EP (1) EP1720905A2 (en)
CA (1) CA2548347A1 (en)
WO (1) WO2005058950A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1827479A1 (en) * 2004-12-09 2007-09-05 Ingenium Pharmaceuticals AG Methods and agents useful in treating conditions characterized by mucus hyperproduction/ hypersecretion
US9533036B2 (en) 2005-11-07 2017-01-03 Microvax, Llc Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
MY183797A (en) 2006-09-18 2021-03-16 Univ Arkansas Compositions and methods of enhancing immune responses
US10174100B1 (en) * 2006-11-06 2019-01-08 Microvax, Llc Multivalent DNA composition for Yersinia pestis
EP3061462B1 (en) 2007-07-02 2019-02-27 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
BRPI0819229B1 (en) 2007-11-01 2019-01-22 The Board Of Trustees Of The University Of Arkansas vaccines to boost immune reactions against eimeria
NZ601609A (en) 2010-01-21 2014-08-29 Univ Arkansas Vaccine vectors and methods of enhancing immune responses
JP5746333B2 (en) 2010-06-09 2015-07-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Vaccines and methods for reducing Campylobacter infection
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014127185A1 (en) 2013-02-14 2014-08-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
MY173901A (en) 2013-03-15 2020-02-26 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to enteric pathogens
CN104345152B (en) * 2013-08-08 2016-09-21 中国人民解放军第二军医大学东方肝胆外科医院 MUC15 Yu p-AKT application in preparing prognosis in hcc assessment test kit
CA2974237C (en) * 2015-01-09 2021-07-20 Etubics Corporation Methods and compositions for combination immunotherapy
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
JP6744318B2 (en) 2015-02-06 2020-08-26 ヒート バイオロジクス，インコーポレイテッド Vector co-expressing vaccine and costimulatory molecule
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
AU2017260323B2 (en) 2016-05-03 2023-11-16 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056602A2 (en) * 2000-02-02 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056602A2 (en) * 2000-02-02 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DAKAPPAGARI N K ET AL: "A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 170, no. 8, 15 April 2003 (2003-04-15), pages 4242 - 4253, XP002290185, ISSN: 0022-1767 *
DIEHL L ET AL: "CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 5, no. 7, July 1999 (1999-07-01), pages 774 - 779, XP002153727, ISSN: 1078-8956 *
MOINGEON P: "Cancer vaccines", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 11-12, 8 December 2001 (2001-12-08), pages 1305 - 1326, XP004313943, ISSN: 0264-410X *
TANG YUCHENG ET AL: "Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.", BLOOD. 1 NOV 2004, vol. 104, no. 9, 1 November 2004 (2004-11-01), pages 2704 - 2713, XP009048261, ISSN: 0006-4971 *
XIANG R ET AL: "A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 167, no. 8, 15 October 2001 (2001-10-15), pages 4560 - 4565, XP002247590, ISSN: 0022-1767 *
ZHANG L ET AL: "An adenoviral vector cancer vaccine that delivers a tumor-asociated antigen/CD40 ligand fusion protein to dendritic cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 100, no. 25, 9 December 2003 (2003-12-09), pages 15101 - 15106, XP002978256, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2548347A1 (en) 2005-06-30
WO2005058950A2 (en) 2005-06-30
EP1720905A2 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
WO2005058950A3 (en) Methods for generating immunity to antigen
WO2007056266A3 (en) Cd40 ligand fusion protein vaccine
WO2004044176A3 (en) Adenoviral vector vaccine
WO2006130525A3 (en) Methods for immunotherapy of cancer
WO2004032865A3 (en) Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
WO2006078294A3 (en) Alphavirus vectors for respiratory pathogen vaccines
DE69834671D1 (en) Immune response against HPV antigens produced by compositions containing an HPV antigen and a stress protein or an expression vector capable of expressing these proteins
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
EA023888B1 (en) Replication-defective flavivirus vaccines and vaccine vectors
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2002034205A3 (en) Using heat shock proteins to increase immune response
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
IL182357A0 (en) Malaria prime/boost vaccines
WO2004084939A8 (en) Hiv-peptide-carrier-conjugates
SG148997A1 (en) Powders comprising low molecular dextran and methods of producing those powders
HUP0401534A2 (en) Modified factor ix
WO2002069907A8 (en) Anti-neovasculature preparations for cancer
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
WO2005035556A3 (en) Sars-coronavirus virus-like particles and methods of use
WO2005051991A3 (en) Mucin antigen vaccine
WO2001056602A3 (en) Cd40 ligand adjuvant for respiratory syncytial virus
WO2004043399A3 (en) Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
CY1109257T1 (en) CHEMICAL PROTEINS L1 OF JUV 16 HUMAN PATIENTS CONTAINING L2 Peptide, Similar to Virus Particles Prepared by
WO2003017032A3 (en) Computer-based methods of designing molecules
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2548347

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004813939

Country of ref document: EP

Ref document number: 2006544078

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004813939

Country of ref document: EP